Skip to main menu | Skip to main content
For Media Inquiries, Please Contact:

Jordan Berman
Vice President,
Global Corporate Communications

Apotex Inc.
  150 Signet Drive
North York,
ON, M9L 1T9
Canada

  416-401-7487
  Email

Press Center

Dec 16, 2022
Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.

New partnership between Apotex and Accessa
Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox and Apo-Deferasirox (Type J) products.

Montreal, December 16 2022 - Accessa, a wholly owned subsidiary of the Association québécoise des pharmaciens propriétaires (AQPP), announces the start of its collaboration with Apotex Inc. and becomes patient support program manager in Quebec for Apo-Deferasirox™ and Apo-Deferasirox (Type J)™* generic products. This product is used in patients suffering from iron overload, especially when treating anemia with frequent transfusions.

Accessa and its network of community pharmacies offer integrated solutions to democratize access to medicines, facilitate the patient journey and optimize treatment. Through Accessa's programs, patients can benefit from comprehensive management of their treatment by their own community pharmacist, thereby promoting adherence to treatment.

“We are pleased to have the support of Apotex who recognizes the relevance of Accessa's unique model. Everyone benefits from having community pharmacists involved in the management of patient support programs, not only because they are accessible, but because they are the drug experts and know the entirety of their patients' pharmacological records,” says Jean Bourcier, President of Accessa.

Apotex believes that community pharmacists make a valuable contribution to quality of care and recognizes the essential role they play in the overall management of their patients’ pharmaceutical treatment.

“Apotex is pleased to be launching this program with Accessa for Apo-Deferasirox and Apo-Deferasirox (Type J). We know that patients in Quebec value the advice and support provided by pharmacists,” says Nick Boorman, Vice President, Marketing. “This collaboration demonstrates our commitment to the profession and will enable us to achieve our goal of providing access to innovative, affordable and high-quality medicines.”

Through this partnership, Accessa further expands its offering for specialty generics.

About Accessa
Created in 2019, Accessa manages a new generation of patient support programs. Established by Québec’s pharmacist owners through the Association québécoise des pharmaciens propriétaires (AQPP), Accessa’s mission is to deliver the most accessible, effective and ethical patient support programs possible to meet the rapid growth of specialty drug prescriptions and the growing needs of patients for complex therapeutic follow-up.

Accessa’s goal is to democratize access to specialty drugs for patients with chronic or rare diseases so that they can benefit from comprehensive treatment management by their pharmacist, the healthcare professional who is most familiar with their medication history.

By relying on a large network of highly qualified community pharmacists in all regions, Accessa enables Quebecers to benefit from the proximity of their pharmacist in order to optimize their treatment.

About Apotex Inc.
Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information visit: www.apotex.com.

*Apo-Deferasiroxand Apo-Deferasirox (Type J) are trademarks owned by Apotex Inc.

- 30 -

Information:
Viviane Ross
Senior Advisor - Public affairs
info@accessa.ca
www.accessa.ca